What is HC Wainwright’s Forecast for ZVRA FY2024 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at HC Wainwright lowered their FY2024 EPS estimates for shares of Zevra Therapeutics in a report released on Wednesday, November 20th. HC Wainwright analyst O. Livnat now expects that the company will post earnings per share of ($1.92) for the year, down from their prior forecast of ($1.74). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.77 EPS and FY2027 earnings at $1.86 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the business earned ($0.40) earnings per share.

Several other research analysts also recently issued reports on the stock. Guggenheim assumed coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price objective on the stock. Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Finally, Roth Mkm raised their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Trading Up 5.0 %

NASDAQ ZVRA opened at $9.59 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm’s fifty day moving average price is $8.16 and its 200 day moving average price is $6.60. The company has a market capitalization of $511.65 million, a price-to-earnings ratio of -4.63 and a beta of 1.93. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.64.

Institutional Trading of Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ZVRA. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at about $474,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares during the period. Simplify Asset Management Inc. acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at about $833,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Zevra Therapeutics in the first quarter valued at about $64,000. Finally, Vanguard Group Inc. lifted its stake in shares of Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after purchasing an additional 58,866 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.